[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345406-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345406-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-applicability-of-the-21-gene-assay-to-inform-chemotherapy-benefit-in-lymph-node-positive-hormone-receptor-positive-male-breast-cancer","The applicability of the 21-gene assay to inform chemotherapy benefit in lymph node positive hormone receptor positive male breast cancer","","Purpose: Determine whether chemotherapy decisions guided by the 21-gene Oncotype DX Recurrence Score (RS) improve overall survival in men with hormone receptor positive (HR+) HER2-negative, lymph node positive breast cancer (LN+). Methods: Retrospective cohort of adults with HR+ HER2-, 1–3 axillary LN+, diagnosed 2004–2020, using National Cancer Database; RS low 0–13, intermediate 14–25, high ≥26. Results: No chemotherapy–OS association in males across RS categories; women ≤50 and >50 showed OS improvement with chemotherapy in intermediate/high RS. Conclusion: RS relates to OS in both sexes, but predicts chemotherapy benefit in women, not men.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-applicability-of-the-21-gene-assay-to-inform-chemotherapy-benefit-in-lymph-node-positive-hormone-receptor-positive-male-breast-cancer/345406/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-applicability-of-the-21-gene-assay-to-inform-chemotherapy-benefit-in-lymph-node-positive-hormone-receptor-positive-male-breast-cancer/345406.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s primary purpose?","Question",{"text":63,"@type":64},"To determine whether giving chemotherapy based on the 21-gene Oncotype DX Recurrence Score (RS) affects overall survival in men with HR+ HER2-negative, lymph node positive breast cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients selected and how were RS risk groups defined?",{"text":68,"@type":64},"A retrospective cohort used the National Cancer Database for adults diagnosed 2004–2020 with HR+ HER2-, 1–3 axillary LN+ and a valid Oncotype DX RS assay. RS groups were low (0–13), intermediate (14–25), and high (≥26).",{"name":70,"@type":61,"acceptedAnswer":71},"Did chemotherapy improve overall survival in men according to RS risk?",{"text":72,"@type":64},"No. In stratified adjusted models, chemotherapy receipt showed no association with overall survival in males for all RS risk groups.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345406,1790189066,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Breast Cancer Research and Treatment (2026) 217:36 [https://doi.org/10.1007/s10549-026-07978-6](https://doi.org/10.1007/s10549-026-07978-6)  \nRESEARCH  \nThe applicability of the 21-gene assay to inform chemotherapy benefit in lymph node positive hormone receptor positive male breast cancer  \nAnu G. Gaba1 · Li Cao2 · Rebecca J. Renfrew3  \nReceived: 26 January 2026 / Accepted: 18 April 2026 / Published online: 20 May 2026 © The Author(s) 2026  \nAbstract  \nPurpose Our study aimed to determine if chemotherapy administration based on the 21-gene Oncotype DX Recurrence Score (RS) in men with hormone receptor positive (HR+) Her2 negative (Her2-) lymph node positive(LN+) breast cancers (BC) impacted overall survival (OS) .  \nPatients and methods We conducted a retrospective cohort study on adult men and women with HR+ Her2-, 1–3 axillary LN +BC, with a valid oncotype DX RS assay, diagnosed between the years 2004–2020, using the National Cancer Database. RS risk categories were defined as low risk: 0–13, intermediate risk:14–25, and high risk: ≥26 .  \nResults Of the 77,820 patients included in the study, 900 (1.2%) were male and 76,920 (98.8%) were female. Higher RS (both as a continuous and categorical variable) was significantly associated with worse OS in males (p= 0.003 continuous, p = 0.006 categorical), females ≤ 50years old and females > 50 years old (p\u003C 0.001 both continuous and categorical, in both groups) . In the stratified adjusted models, there was no association between receipt of chemotherapy and OS in males for all RS risk groups. Conversely, chemotherapy improved OS for women ≤ 50 and for women >50 who belonged to the intermediate and high RS risk groups (p= 0.001 and p\u003C 0.001 respectively (women ≤ 50); p= 0.005 and p\u003C 0·001 respectively (women > 50)) .  \nConclusion RS as determined by the Oncotype DX assay is associated with OS in men and women with HR+ Her2-LN+ BC. However, RS is not an indicator of the benefit of chemotherapy on OS in men, in contrast to women, with HR+ Her2-LN+ BC.  \nKeywords Oncotype DX assay · Recurrence score · Male breast cancer · National cancer database · Lymph node positive  \n􀀍 Anu G. Gaba [Anu.gaba@sanfordhealth.org](Anu.gaba@sanfordhealth.org)  \nLi Cao  \n[li.cao@sanfordhealth.org](li.cao@sanfordhealth.org)  \nRebecca J. Renfrew  \n[rebecca.renfrew@sanfordhealth.org](rebecca.renfrew@sanfordhealth.org)  \n1 Sanford Roger Maris Cancer Center, Department of Medicine, University of North Dakota, 820 4th Street N, Fargo, ND 58102, USA  \n2 Sanford Center for Biobehavioral Research, 120 8th St S, Fargo, ND 58103, USA  \n3 Sanford Health, 820 4th Street N, Fargo, ND 58102, USA  \nBackground  \nThe Oncotype DX assay is based on the expression of 16 tumor associated genes and 5 reference genes which is then translated into a Recurrence Score (RS) with values ranging from 0 to 100, where a high RS indicates a higher risk of recurrence (ROR) [1] . The utility of the 21-gene Oncotype DX RS assay in predicting benefit from chemotherapy was first validated prospectively in lymph node negative(LN-) women, stage I and II, hormone receptor positive (HR+) Her2 negative (Her2-) breast cancer (BC) [2, 3], and subsequently in HR+ Her2-lymph node positive (LN+) women [4, 5] .  \nThe validity of the Oncotype DX RS assay was first studied in HR+ Her2-LN+ post-menopausal women in a retrospective analysis of tumor samples from patients recruited to the prospective Southwest Oncology Group (SWOG)  \nS8814 trial, which had shown that chemotherapy with tamoxifen improved the survival benefit when compared to tamoxifen alone [4] . The retrospective analysis showed that some patients with lower RS did not benefit from the addition of chemotherapy. This led to a confirmatory prospective randomized trial, RxPONDER study, in pre- and post-menopausal HR+ Her2- LN+ (1–3 axillary LN+) women with BC, RS ≤ 25, to assess the benefit of chemotherapy in addition to antihormonal therapy (AHT) [5] . The RxPONDER study showed that pre-menopaus","cbCailf0a0wkwNhz","https://ap.wps.com/l/cbCailf0a0wkwNhz","pdf",1302618,"English","# Abstract\n## Purpose\n## Patients and methods\n## Results\n## Conclusion\n# Background\n## Oncotype DX and recurrence score\n## Prior prospective and retrospective evidence\n## Sex differences and existing findings\n# Methodology","[{\"question\":\"What was the study’s primary purpose?\",\"answer\":\"To determine whether giving chemotherapy based on the 21-gene Oncotype DX Recurrence Score (RS) affects overall survival in men with HR+ HER2-negative, lymph node positive breast cancer.\"},{\"question\":\"How were patients selected and how were RS risk groups defined?\",\"answer\":\"A retrospective cohort used the National Cancer Database for adults diagnosed 2004–2020 with HR+ HER2-, 1–3 axillary LN+ and a valid Oncotype DX RS assay. RS groups were low (0–13), intermediate (14–25), and high (≥26).\"},{\"question\":\"Did chemotherapy improve overall survival in men according to RS risk?\",\"answer\":\"No. In stratified adjusted models, chemotherapy receipt showed no association with overall survival in males for all RS risk groups.\"}]","The applicability of the 21-gene assay to inform chemotherapy benefit in lymph node positive hormone receptor positive male breast cancer | PDF",1790057565,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1378e5901eb61554793a0a109dfff8a.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6419470224ab51f7ebadb613f7164a8d.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f58bf3012e22d1a5b55a7a4697487879.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e596a66217d020aa5a597b7ba8337fe6.webp",980,1301]